louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04143542: Trunks Body Blocks for Postoperative Analgesia in Abdominal Surgery
Official title: Comparison of Quadratus Lumborum Block 2 and Transversus Abdominis Plan Block for Postoperative Analgesia in Abdominal Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Analgesia
Block
Keywords: quadratus lumborum block
transversus abdominis block
postoperative analgesia
Lead sponsor: Diskapi Teaching and Research Hospital
Sponsor class: OTHER
First posted: 2019-10-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: This study aims to the comparison of Quadratus Lumborum Block 2 and Transversus Abdominis Plan Block for Postoperative Analgesia in Abdominal Surgery

Detailed description: This study aims to the comparison of Quadratus Lumborum Block 2 and Transversus Abdominis Plan Block for Postoperative Analgesia in Abdominal Surgery.

In abdominal surgeries, USG guided body blocks are performed for postoperative analgesia. For this purpose, Transversus Abdominis Plan Block (TAPB) and Quadratus Lumborum Block 2 (QLB 2) are frequently used blocks.

The aim of this study was to evaluate for postoperative analgesia of preoperative trunk blocks, intraoperative hemodynamic changes with the unblocked control group, Modified Aldrete Recovery Score (MADS) 9 in the recovery unit, Numerical pain scale (NRS) in the service department, It is aimed to examine and compare the time it reaches on the 1st, 2nd and 24th hours after this period. Patient satisfaction is also evaluated in the ward.

Eligibility criteria: Inclusion Criteria:

Abdominal surgery

Exclusion Criteria:

Cardio-respiratory disease Anti-inflammatory treatment Cognitive disorders Written consent form haven't get history of relevant drug allergy infection of the skin at the site of the needle puncture area coagulopathy

Primary outcomes:
measure: Postoperative pain
timeFrame: 1 hours
measure: Postoperative pain
timeFrame: 2 hours
measure: Postoperative pain
timeFrame: 4 hours
measure: The degree of postoperative pain
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Diskapi Yildirim Beyazit Education and Research Hospital
name: Ceyda Ozhan Caparlar
role: STUDY_DIRECTOR
References:
Clinical trial NCT00637442: Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)
Official title: Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alzheimer's Disease
Lead sponsor: University Hospital, Bonn
Sponsor class: OTHER
Collaborators: name: Federal Ministry of Health, Germany
First posted: 2008-03-18
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease


Eligibility criteria: Inclusion Criteria:

* Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA
* Underwritten study consent
* No treatment with acetylcholinesterase inhibitors
* Mini-Mental-State Examination: 12-25 points
* Age: 50-80 Years
* Orale contraception for women of child-bearing age

Exclusion Criteria:

* Mental Disorders
* Other Diseases of the CNS
* Severe Illness
* Contraindication for MRI-Scan
* Contraindication for Galantamin (Reminyl retard®)
* Participation at other clinical trials

Primary outcomes:
measure: Cerebral perfusion
timeFrame: baseline and after 12 weeks
Secondary outcomes:
measure: Change of Alzheimer Disease Assessment Scale, cognitive part (ADAScog)
timeFrame: baseline, after 12 and 24 weeks
measure: Alzheimer's Disease Functional Assessment and Change Scale (ADFACS)
timeFrame: baseline, after 12 and 24 weeks
measure: Neuropsychiatric Inventory (NPI)
timeFrame: baseline, after 12 and 24 weeks
measure: Mini-Mental-Status-Examination (MMSE)
timeFrame: baseline, after 12 and 24 weeks
Other outcomes:
Locations:
city: Bonn
country: Germany
facility: Department of Psychiatry, University Bonn
Study officials:
affiliation: University Bonn
name: Frank Jessen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06166342: Efficacy Evaluation of TCI153 Probiotics for Skin Beautification
Official title: Efficacy Evaluation of TCI153 Probiotics for Skin Beautification
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Skin Condition
Lead sponsor: TCI Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2023-12-12
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To assess TCI153 prebiotics product on skin condition improvement


Eligibility criteria: Inclusion Criteria:

* Healthy adults aged above 18 years old

Exclusion Criteria:

* Subject who is not willing to participate in this study.
* Patients with diseases of the skin, liver, kidney.
* Subjects who have known cosmetic, drug or food allergies, difficulty in digestive tract absorption or disorder.
* Female who is pregnant or nursing or planning to become pregnant during the course of the study.
* Received facial laser therapy, chemical peeling or UV overexposure (\> 3 hr/week) in the past 4 weeks.
* Constant drug use
* Students who are currently taking courses taught by the principal investigator of this trial.
* Subject who is not willing to have their photos published in public.

Primary outcomes:
measure: The change of skin wrinkles
timeFrame: Change from Baseline skin wrinkles at 8 weeks
measure: The change of skin texture
timeFrame: Change from Baseline skin texture at 8 weeks
measure: The change of skin melanin index
timeFrame: Change from Baseline skin melanin index at 8 weeks
measure: The change of skin L* value
timeFrame: Change from Baseline L* value at 8 weeks
Secondary outcomes:
measure: The change of skin elasticity
timeFrame: Change from Baseline skin elasticity at 8 weeks
measure: The change of skin erythema index
timeFrame: Change from Baseline skin erythema index at 8 weeks
measure: The change of skin moisture
timeFrame: Change from Baseline skin moisture at 8 weeks
measure: The change of transepidermal water loss (TEWL)
timeFrame: Change from Baseline TEWL at 8 weeks
measure: The change of skin pores
timeFrame: Change from Baseline AGEs at 8 weeks
measure: The change of gut microbiome composition
timeFrame: Change from Baseline AGEs at 8 weeks
Other outcomes:
measure: The change of liver function biomarkers (AST, ALT) of blood
timeFrame: Change from Baseline liver function biomarkers at 8 weeks
measure: The change of renal function biomarkers (creatinine, BUN) of blood
timeFrame: Change from Baseline renal function biomarkers at 8 weeks
measure: The change of fasting blood glucose
timeFrame: Change from Baseline blood glucose at 8 weeks
measure: The change of sialic acid
timeFrame: Change from Baseline sialic acid at 8 weeks
measure: The change of Epidermal Growth Factor (EGF)
timeFrame: Change from Baseline EGF at 8 weeks
Locations:
city: Tainan City
country: Taiwan
facility: Chia Nan University of Pharmacy & Science
Study officials:
affiliation: Chia Nan University of Pharmacy ＆ Science
name: Chia-Hua Liang
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05806242: EMS-I: Validation of the Italian Version of the Elderly Mobility Scale
Official title: EMS-I: Validation of the Italian Version of the Elderly Mobility Scale
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Physical Functional Performance
Keywords: elderly subjects
rehabilitation
Elderly Mobility Scale
Lead sponsor: Istituto Nazionale di Ricovero e Cura per Anziani
Sponsor class: OTHER
First posted: 2023-04-10
Enrollment: 50
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Elderly frail in-patients

Brief summary: This study is an observational study that aims to validate the Elderly Mobility Scale (EMS) in Italian (EMS-I) by comparison with the Barthel Index scale, already validated in Italian. Furthermore this study wants to evaluate the inter-rater reliability comparing the scores assigned to the same sample of patients by two independent evaluators. The study population includes 50 elderly in-patients eligible for physiotherapy.

Detailed description: This study is an observational study that aims to validate the Elderly Mobility Scale (EMS) in Italian (EMS-I) by comparison with the Barthel Index scale, already validated in Italian.

The Elderly Mobility Scale (EMS) is considered a suitable tool to assess basic motor function in hospitalized geriatric patients. It has shown good psychometric characteristics.

The study process requires a standardized translation protocol, including forward and backward translation. The protocol provides enrollment of 50 geriatric in-patients eligible for physiotherapy admitted to IRCCS-INRCA Hospital. Two physiotherapists independently evaluate the same enrolled patient with Italian EMS (EMS-I) and Barthel Index.

Eligibility criteria: Inclusion Criteria:

* Patients admitted to the IRCCS-INRCA Hospital
* Request for physiotherapy evaluation
* Sign of the informed consent

Exclusion Criteria:

* Lack of Medical approval for sitting and standing position.

Primary outcomes:
measure: Italian Elderly Mobility Scale (EMS) in Italian (EMS-I) validity
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Ancona
country: Italy
facility: IRCCS INRCA Hospital
Study officials:
References:
Clinical trial NCT06435442: PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
Official title: A Phase 1 Study to Evaluate the Safety and PK/PD Drug-drug Interaction Between Epaminurad and Naproxen or to Assess the Safety and Multiple-Dose PK/PD Characteristics of Epaminurad in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: PHASE1
Conditions: Healthy
Lead sponsor: JW Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2024-05-30
Enrollment: 48
Sex: ALL
Minimum age (years): 19
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: PART 1: A open-label, multiple-dose, single group/ PART 2: A placebo-controlled, randomized, double-blind, multiple-dose, parallel group
Primary purpose: TREATMENT

Brief summary: A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Volunteers

Detailed description: Part 1: to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and Naproxen in Healthy Koreans/ Part 2: to evaluate the safety, PK/PD of Epaminurad in Healthy Caucasians

Eligibility criteria: Inclusion Criteria:

1. Age: 19\~50
2. Weight: between 50.0 kg\~90.0 kg, Body Mass Index(BMI): 18.0 kg/m\^2 or heavier and below 30.0 kg/m\^2
3. Part 1: Korean/ Part 2: Caucasian

Exclusion Criteria:

1. Medical history- chronic liver disease, acute gout attack, uric acid stone, diabetes, hypertension, hyperlipidemia or lipid abnormality
2. Clinical examination- eGFR (CKD-EPI) \< 90mL/min/1.73m\^2, Serum uric acid \< 3 mg/dL or \> 7 mg/dL, AST (SGOT), ALT (SGPT) \> upper limit of normal ranges X 1.5, Total bilirubin, γ-GTP \> upper limit of normal ranges X 1.5, CK \> upper limit of normal ranges X 2, Positive serologic results Cystatin C \> 1.26mg/L (man), \> 1.19 mg/L (woman)

Primary outcomes:
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: 5 days
measure: Area under the plasma concentration versus time curve (AUC)
timeFrame: 7 days
measure: Peak plasma concentrations (Cmax)
timeFrame: 7 days
measure: Peak plasma concentrations (Cmax)
timeFrame: 5 days
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Kyung-sang Yu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03199742: Evaluation of a Mobile Phone App for Veterans With PTSD
Official title: Evaluation of a Mobile Phone App for Veterans With PTSD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stress Disorders, Post-Traumatic
Veterans
Lead sponsor: VA Palo Alto Health Care System
Sponsor class: FED
First posted: 2017-06-27
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are randomized to receive one of 2 forms of the mobile phone application being tested in this study: with and without personalized coaching. Among those who receive coaching, participants will receive either peer-based coaching messages, clinician-based coaching messages, or automated messages.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate a mobile phone app designed to help Veterans with PTSD. Participants in this study will be randomized to receive one of 2 possible mobile phone apps. The term "randomized" means that which app a participant receives will not be based on any characteristic or behavior of the participant, but will be determined solely by chance like a flip of a coin.

Detailed description: Participants will receive access to the mobile app "PTSD Coach". Participants will be randomized (by computerized coin flip) to one of two versions of the mobile app. All versions of the app will provide comprehensive information and tools for managing trauma symptoms, but one version of the app will provide personalized, confidential coaching messages delivered by either a Veteran peer or clinical psychologist. Participants will be asked to complete an online survey before using the mobile phone application and again 8 weeks later. Participants will be provided with the option to complete a telephone interview after 8 weeks of using the mobile phone application. To be eligible, participants must be a U.S. military Veteran, age 18 or older, have received a previous diagnosis of PTSD, and own an iPhone or iPad device.

Eligibility criteria: Inclusion Criteria:

* U.S. military Veteran
* age 18 or older
* previously diagnosed with PTSD
* own an iPhone or iPad device

Exclusion Criteria:

* no previous history of PTSD

Primary outcomes:
measure: PTSD Checklist 5
timeFrame: 8 weeks
measure: Functional Well-Being
timeFrame: 8 weeks
measure: Engagement with the Application
timeFrame: 8 weeks
Secondary outcomes:
measure: Self-Efficacy for Coping
timeFrame: 8 weeks
measure: Perceived Helpfulness of Intervention
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Menlo Park
country: United States
facility: VA Palo Alto Health Care System Menlo Park Division
state: California
Study officials:
References:
Clinical trial NCT00541242: Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Ocular Hypertension
Glaucoma
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2007-10-10
Enrollment: 586
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study will compare the safety and efficacy of Bimatoprost and Latanoprost in patients with glaucoma or ocular hypertension


Eligibility criteria: Inclusion Criteria:

* Ocular hypertension or chronic glaucoma
* Patient requires IOP-lowering therapy in both eyes

Exclusion Criteria:

* Uncontrolled medical conditions
* Hypersensitivity to study medications

Primary outcomes:
measure: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 12
timeFrame: Baseline, Week 12
measure: Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Week 18
timeFrame: Baseline, Week 18
Secondary outcomes:
Other outcomes:
Locations:
city: Newport Beach
country: United States
state: California
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01329042: Efficacy of Potassium Sodium Hydrogen Citrate Therapy on Renal Stone Recurrence and/or Residual Fragments After Shockwave Lithotripsy and Percutaneous Nephrolithotomy in Calcium Oxalate Urolithiasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Kidney Calculi
Keywords: Potassium sodium citrate
stone recurrence
ESWL
PCNL
Hypocitraturia
intervention
Lead sponsor: Ouiheng International Healthcare Co., Ltd
Sponsor class: INDUSTRY
Collaborators: name: Chiang Mai University
name: Prince Songkla University
name: Chulalongkorn University
name: Siriraj Hospital
First posted: 2011-04-05
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Extracorporeal shock wave lithotripsy (ESWL) and Percutaneous nephrolithotomy (PCNL) become the therapy of choice for renal stone. Although providing good results, stone recurrence is usually found as the therapies do not change the underlying metabolic abnormality. Among the metabolic disorders, hypocitraturia is an important risk factor for calcium nephrolithiasis. This study evaluate the preventive effects of potassium sodium citrate on stone recurrence as well as stone growth post ESWL or PCNL, in patients with calcium-containing stones.


Eligibility criteria: Inclusion Criteria:

* age \> 18 years
* stone free or had residual calcium oxalate stone fragments with a less than 4 mm. diameter at eight weeks after ESWL or PCNL

Exclusion Criteria:

* renal tubular obstruction
* serum creatinine \> 2 mg/dl
* urinary tract infection (bacteria \> 100,000 in urine culture)
* hypersensitive or contraindication to Potassium sodium hydrogen citrate
* insertion Double-J Stent
* history of arrhythmia, myocardial infarction or digitalis administration

Primary outcomes:
measure: rate of stone recurrence or stone growth
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Division of Urology, Department of Surgery, Chiangmai University, Thailand
name: Bannakij Lojanapiwat, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01973842: Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients
Official title: Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients Undergoing Ovarian Stimulation for IVF With GnRH Antagonists and Recombinant FSH.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Subfertility
Keywords: GnRH agonist
OHSS
Triggering final oocyte maturation
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
Collaborators: name: Eugonia IVF Unit, Athens, Greece
First posted: 2013-11-01
Enrollment: 90
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present study aims to investigate whether the dosage of the GnRH agonist used for triggering final oocyte maturation affects the maturity of the oocytes retrieved in high risk for OHSS patients undergoing ovarian stimulation for IVF using GnRH antagonists and recombinant FSH.

Detailed description: Three different doses of GnRH agonist (0.1mg, 0.2mg or 0.4 mg) will be used randomly to trigger final oocyte maturation. The primary outcome measure will be the percentage of mature oocytes retrieved.

Secondary outcomes will include: number of oocytes retrieved, oocyte recovery rate (number of oocytes retrieved/ number of follicles \>11mm in diameter on the day of triggering), fertilization rates and OHSS occurrence.

Serum LH, FSH, E2, PRG levels will be assessed at 8-36 hours following agonist administration and on days 3-4-7-10 after triggering final oocyte maturation.

Eligibility criteria: Inclusion Criteria: Patients undergoing ovarian stimulation for IVF using GnRH antagonist protocol

* Age \< 40 years
* Anticipated high ovarian response

Exclusion Criteria:

* Endometriosis \> than grade II
* One ovary

Primary outcomes:
measure: Percentage of mature oocytes retrieved
timeFrame: 36 hours post GnRH agonst administration
Secondary outcomes:
measure: total number of oocytes retrieved
timeFrame: 36 hours post GnRH agonist administration
measure: oocyte recovery rate
timeFrame: 36 hours post GnRH agonist administration
measure: Fertilization rate
timeFrame: Day 1 post oocyte retrieval
measure: Serum LH, FSH, E2, PRG levels
timeFrame: 8-36 hours post triggering and on days 3-4-7-10 after GnRH agonist administration
measure: Duration of luteal phase
timeFrame: 16 days
measure: OHSS occurrence
timeFrame: 16 days post triggering
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Eugonia IVF Unit
city: Thessaloniki
country: Greece
facility: Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki
Study officials:
affiliation: Unit of Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki Thessaloniki, Greece
name: Efstratios Kolibianakis, MD, MSc, PhD
role: PRINCIPAL_INVESTIGATOR
References: